ANI Pharmaceuticals Inc (ANIP) - Total Assets
Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) holds total assets worth $1.44 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ANIP cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
ANI Pharmaceuticals Inc - Total Assets Trend (1998–2025)
This chart illustrates how ANI Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See ANIP net assets for net asset value and shareholders' equity analysis.
ANI Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
ANI Pharmaceuticals Inc's total assets of $1.44 Billion consist of 52.3% current assets and 47.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.8% |
| Accounts Receivable | $281.08 Million | 19.5% |
| Inventory | $143.07 Million | 9.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $479.53 Million | 33.3% |
| Goodwill | $62.48 Million | 4.3% |
Asset Composition Trend (1998–2025)
This chart illustrates how ANI Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of ANI Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ANI Pharmaceuticals Inc's current assets represent 52.3% of total assets in 2025, a decrease from 84.6% in 1998.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2025, down from 82.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is intangible assets at 33.3% of total assets.
ANI Pharmaceuticals Inc Competitors by Total Assets
Key competitors of ANI Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
|
Akums Drugs and Pharmaceutical
NSE:AKUMS
|
India | Rs51.59 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676
|
China | CN¥1.95 Billion |
ANI Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.71 | 2.72 | 2.21 |
| Quick Ratio | 2.19 | 2.02 | 1.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $475.00 Million | $334.00 Million | $100.03 Million |
ANI Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between ANI Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 1.21 |
| Asset Growth Rate (YoY) | 12.2% |
| Total Assets | $1.44 Billion |
| Market Capitalization | $1.74 Billion USD |
Valuation Analysis
Above Book Valuation: The market values ANI Pharmaceuticals Inc's assets above their book value (1.21x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ANI Pharmaceuticals Inc's assets grew by 12.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual total assets of ANI Pharmaceuticals Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.44 Billion | +12.21% |
| 2024-12-31 | $1.28 Billion | +41.94% |
| 2023-12-31 | $904.42 Million | +18.99% |
| 2022-12-31 | $760.09 Million | -1.49% |
| 2021-12-31 | $771.60 Million | +67.31% |
| 2020-12-31 | $461.19 Million | +0.96% |
| 2019-12-31 | $456.79 Million | +6.08% |
| 2018-12-31 | $430.60 Million | +4.48% |
| 2017-12-31 | $412.14 Million | +27.65% |
| 2016-12-31 | $322.86 Million | +13.18% |
| 2015-12-31 | $285.26 Million | +8.17% |
| 2014-12-31 | $263.71 Million | +492.60% |
| 2013-12-31 | $44.50 Million | +14.78% |
| 2012-12-31 | $38.77 Million | -37.85% |
| 2011-12-31 | $62.38 Million | +39.34% |
| 2010-12-31 | $44.77 Million | +22.86% |
| 2009-12-31 | $36.44 Million | +106.10% |
| 2008-12-31 | $17.68 Million | -43.41% |
| 2007-12-31 | $31.24 Million | +39.65% |
| 2006-12-31 | $22.37 Million | +133.65% |
| 2005-12-31 | $9.57 Million | -46.29% |
| 2004-12-31 | $17.83 Million | +86.37% |
| 2003-12-31 | $9.57 Million | +62.68% |
| 2002-12-31 | $5.88 Million | +18.09% |
| 2001-12-31 | $4.98 Million | +62.35% |
| 2000-12-31 | $3.07 Million | -46.94% |
| 1999-12-31 | $5.78 Million | +67.56% |
| 1998-12-31 | $3.45 Million | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more